Discover and read the best of Twitter Threads about #ENZA
Most recents (2)
Folks! We return for #HOTrainees with the exciting #Day2 @myESMO #ESMO20 and some more #practice relevant studies in #breastcancer #ProstateCancer #lungcancer #GI, so sit back, relax and lets go through some data (#HO #trainee-style!) Shout out to @peters_solange @OncoAlert
1. #BreastCancer: We have #monarchE and #IMPassion031 hoping to hear from experts @ErikaHamilton9 @NicoleKuderer @DrSGraff @matteolambe @tmprowell @GeorgeSledge51 @VukovicPetra for more insights- please link to your discussions here for #trainees:
1. A) #monarchE: use of #abemiciclib in HR+, HER2-,high risk #EBC in addition to endocrine therapy.
Current #SOC: adjuvant ET (5-10 years)
#monarchE: #Abemaciclib + ET iDFS HR 0.747, here's a great summary by @ErikaHamilton9 for @OncoAlert :
Current #SOC: adjuvant ET (5-10 years)
#monarchE: #Abemaciclib + ET iDFS HR 0.747, here's a great summary by @ErikaHamilton9 for @OncoAlert :
So @ANZUPtrials #ENZAMEt #PCSM results fro #HRQOL were presented today at #ESMO19, here are some of the headline outcomes 1/5 #InternationalCollaboration #RCT
@ANZUPtrials Acknowledgements usually come last but we can't do these studies without #patients. So our very sincere thanks to the 1125 men living with mHRPC #PCSM who volunteered to take part, have the treatment, & fill out #HRQOL questionnaires! #ENZAMET @anzupartners #ESMO19 2/5
@ANZUPtrials @anzupartners In the @ANZUPTrials #ENZAMET study we measured #HRQOL using @EORTC_QLG's #QLQC30 (global qol, social, physical, emotional, functional domains) & Prostate Cancer module #PR25 at weeks 0, 4, 12, then 12-weekly until clinical progression #PCSM #ESMO19 3/5
